Роль молекулярно-генетической диагностики в выборе терапии при опухолях билиарного тракта

Роль молекулярно-генетической диагностики в выборе терапии при опухолях билиарного тракта

Автор: Митюшкина Н.В., Имянитов Е.Н.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 1 т.23, 2024 года.

Бесплатный доступ

Цель исследования - оценить частоту и клиническое значение различных молекулярно-генетических нарушений при опухолях билиарного тракта и определить оптимальные методы их тестирования. Материал и методы. Проведен поиск литературных источников, содержащих сведения о предиктивных молекулярных маркерах, имеющих значение для выбора терапии при опухолях билиарного тракта, в базах данных PubMed и eLibrary за период с 2010 по 2023 г. В данный обзор включены данные 60 исследований.

Рак билиарного тракта, холангиокарцинома, рак желчного пузыря, таргетная терапия, her2, braf, msi, fgfr2, idh1

Короткий адрес: https://sciup.org/140303740

IDR: 140303740   |   DOI: 10.21294/1814-4861-2024-23-1-130-141

Список литературы Роль молекулярно-генетической диагностики в выборе терапии при опухолях билиарного тракта

  • Banales J.M., Cardinale V., Carpino G., Marzioni M., Andersen J.B., Invernizzi P., Lind G.E., Folseraas T., Forbes S.J., Fouassier L., Geier A., Calvisi D.F., Mertens J.C., Trauner M., Benedetti A., Maroni L., Vaquero J., Macias R.I., Raggi C., Perugorria M.J., Gaudio E., Boberg K.M., Marin J.J., Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5): 261-80. https://doi.org/10.1038/nrgastro.2016.51.
  • Baria K., De Toni E.N., Yu B., Jiang Z., Kabadi S.M., Malvezzi M. Worldwide Incidence and Mortality of Biliary Tract Cancer. Gastro Hep Advances. 2022; 1(4): 618-26. https://doi.org/10.1016/j.gastha.2022.04.007.
  • Valle J.W., Kelley R.K., Nervi B., Oh D.Y., Zhu A.X. Biliary tract cancer. Lancet. 2021; 397(10272): 428-44. https://doi.org/10.1016/S0140-6736-(21)00153-7.
  • Druk I.V., Nechaeva G.I., Lyalyukova E.A., Semenova E.V. Rak zhelchnogo puzyrya: epidemiologiya, faktory riska. Eksperimental'naya i klinicheskaya gastroenterologiya. 2022; (9): 153-60. https://doi.org/10.31146/1682-8658-ecg-205-9-153-160.
  • Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., Sant M., Trama A., Faivre J.; EUROCARE-5 Working Group. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. Eur J Cancer. 2015; 51(15): 2169-78. https://doi.org/10.1016/j.ejca.2015.07.034.
  • Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S.P., Roughton M., Bridgewater J.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273-81. https://doi.org/10.1056/NEJMoa0908721.
  • Okusaka T., Nakachi K., Fukutomi A., Mizuno N., Ohkawa S., Funakoshi A., Nagino M., Kondo S., Nagaoka S., Funai J., Koshiji M., Nambu Y., Furuse J., Miyazaki M., Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103(4): 469-74. https://doi.org/10.1038/sj.bjc.6605779.
  • Oh D.-Y., He A.R., Qin S., Chen L.-T., Okusaka T., Vogel A., Kim J.W., Thatthan S., Lee M.A., Kitano M., Burris H., Bouattour M., Tanasanvimon S., McNamara M.G., Zaucha R., Avallone A., Tan B., Cundom J., Lee C.-K., Takahashi H., Ikeda M., Chen J.-S., Wang J., Makowsky M., Rokutanda N., He P., Kurland J.F., Cohen G., and Valle J.W., for the TOPAZ-1 Investigators. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022; 1(8). https://doi.org/10.1056/EVIDoa2200015.
  • Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klümpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., Ducreux M.; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(2): 127-40. https://doi.org/10.1016/j.annonc.2022.10.506.
  • Ramjeesingh R., Chaudhury P., Tam V.C., Roberge D., Lim H.J., Knox J.J., Asselah J., Doucette S., Chhiber N., Goodwin R. A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada. Curr Oncol. 2023; 30(8): 7132-50. https://doi.org/10.3390/curroncol30080517.
  • Kelley R.K., Ueno M., Yoo C., Finn R.S., Furuse J., Ren Z., Yau T., Klümpen H.J., Chan S.L., Ozaka M., Verslype C., Bouattour M., Park J.O., Barajas O., Pelzer U., Valle J.W., Yu L., Malhotra U., Siegel A.B., Edeline J., Vogel A.; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391): 1853-65. https://doi.org/10.1016/S0140-6736(23)00727-4. Erratum in: Lancet. 2023; 402(10406): 964.
  • Lamarca A., Palmer D.H., Wasan H.S., Ross P.J., Ma Y.T., Arora A., Falk S., Gillmore R., Wadsley J., Patel K., Anthoney A., Maraveyas A., Iveson T., Waters J.S., Hobbs C., Barber S., Ryder W.D., Ramage J., Davies L.M., Bridgewater J.A., Valle J.W.; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021; 22(5): 690-701. https://doi.org/10.1016/S1470-2045(21)00027-9.
  • Galdy S., Lamarca A., McNamara M.G., Hubner R.A., Cella C.A., Fazio N., Valle J.W. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017; 36(1): 141-57. https://doi.org/10.1007/s10555-016-9645-x.
  • Javle M., Borad M.J., Azad N.S., Kurzrock R., Abou-Alfa G.K., George B., Hainsworth J., Meric-Bernstam F., Swanton C., Sweeney C.J., Friedman C.F., Bose R., Spigel D.R., Wang Y., Levy J., Schulze K., Cuchelkar V., Patel A., Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021; 22(9): 1290-300. https://doi.org/10.1016/S1470-2045(21)00336-3.
  • Ohba A., Morizane C., Kawamoto Y., Komatsu Y., Ueno M., Kobayashi S., Ikeda M., Sasaki M., Furuse J., Okano N., Hiraoka N., Yoshida H., Kuchiba A., Sadachi R., Nakamura K., Matsui N., Nakamura Y., Okamoto W., Yoshino T., Okusaka T. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol. 2022; 40(16_suppl). https://doi.org/10.1200/JCO.2022.40.16_suppl.4006.
  • Harding J.J., Fan J., Oh D.Y., Choi H.J., Kim J.W., Chang H.M., Bao L., Sun H.C., Macarulla T., Xie F., Metges J.P., Ying J., Bridgewater J., Lee M.A., Tejani M.A., Chen E.Y., Kim D.U., Wasan H., Ducreux M., Bao Y., Boyken L., Ma J., Garfin P., Pant S.; HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023; 24(7): 772-82. https://doi.org/10.1016/S1470-2045(23)00242-5.
  • Zheng Y., Shen G., Zhang C., Huo X., Xin Y., Fang Q., Guan Y., Zhao F., Ren D., Liu Z., Wang M., Zhao J. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis. Clin Exp Med. 2023; 23(7): 3205-16. https://doi.org/10.1007/s10238-023-01072-7.
  • Goeppert B., Frauenschuh L., Renner M., Roessler S., StenzingerA., Klauschen F., Warth A., Vogel M.N., Mehrabi A., Hafezi M., Boehmer K., von Deimling A., Schirmacher P., Weichert W., Capper D. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014; 27(7): 1028-1034. https://doi.org/10.1038/modpathol.2013.206.
  • Kendre G., Murugesan K., Brummer T., Segatto O., Saborowski A., Vogel A. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023; 78(3): 614-26. https://doi.org/10.1016/j.jhep.2022.11.030.
  • Subbiah V., Kreitman R.J., Wainberg Z.A., Gazzah A., Lassen U., Stein A., Wen P.Y., Dietrich S., de Jonge M.J.A., Blay J.Y., Italiano A., Yonemori K., Cho D.C., de Vos F.Y.F.L., Moreau P., Fernandez E.E., Schellens J.H.M., Zielinski C.C., Redhu S., Boran A., Passos V.Q., Ilankumaran P., Bang Y.J. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023; 29(5): 1103-12. https://doi.org/10.1038/s41591-023-02321-8.
  • Subbiah V., Puzanov I., Blay J.Y., Chau I., Lockhart A.C., Raje N.S., Wolf J., Baselga J., Meric-Bernstam F., Roszik J., Diamond E.L., Riely G.J., Sherman E.J., Riehl T., Pitcher B., Hyman D.M. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discov. 2020; 10(5): 657-63. https://doi.org/10.1158/2159-8290.CD-19-1265.
  • Bekaii-Saab T.S., Yaeger R., Spira A.I., Pelster M.S., Sabari J.K., Hafez N., Barve M., Velastegui K., Yan X., Shetty A., Der-Torossian H., Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation. J Clin Oncol. 2023; 41(25): 4097-4106. https://doi.org/10.1200/JCO.23.00434.
  • Roubal K., Myint Z.W., Kolesar J.M. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.Am J Health Syst Pharm. 2020; 77(5): 346-51. https://doi.org/10.1093/ajhp/zxz329.
  • Uson Junior P.L.S., Borad M.J. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond. Semin Liver Dis. 2023; 43(2): 218-25. https://doi.org/10.1055/a-2049-3149.
  • Abou-Alfa G.K., Sahai V., Hollebecque A., Vaccaro G., Melisi D., Al-Rajabi R., Paulson A.S., Borad M.J., Gallinson D., Murphy A.G., Oh D.Y., Dotan E., Catenacci D.V., Van Cutsem E., Ji T., Lihou C.F., Zhen H., Féliz L., Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5): 671-84. https://doi.org/10.1016/S1470-2045(20)30109-1. Erratum in: Lancet Oncol. 2024; 25(1).
  • Javle M., Roychowdhury S., Kelley R.K., Sadeghi S., Macarulla T., Weiss K.H., Waldschmidt D.T., Goyal L., Borbath I., El-Khoueiry A., Borad M.J., Yong W.P., Philip P.A., Bitzer M., Tanasanvimon S., Li A., Pande A., Soifer H.S., Shepherd S.P., Moran S., Zhu A.X., Bekaii-Saab T.S., Abou-Alfa G.K. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6(10): 803-15. https://doi.org/10.1016/S2468-1253(21)00196-5.
  • Javle M., King G., Spencer K., Borad M.J. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023; 28(11): 928-43. https://doi.org/10.1093/oncolo/oyad149.
  • Bitzer M., Spahn S., Babaei S., Horger M., Singer S., Schulze-Osthoff K., Missios P., Gatidis S., Nann D., Mattern S., Scheble V., Nikolaou K., Armeanu-Ebinger S., Schulze M., Schroeder C., Biskup S., Beha J., Claassen M., Ruhm K., Poso A., Malek N.P. Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. NPJ Precis Oncol. 2021; 5(1): 80. https://doi.org/10.1038/s41698-021-00220-0.
  • Hempel L., Lapa C., Dierks A., Gaumann A., Scheiber J., Veloso de Oliveira J., Philipp P., Oyarzun Laura C., Wesarg S., Robert S., Hempel D. A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma. Ther Adv Med Oncol. 2022; 14. https://doi.org/10.1177/17588359221125096.
  • Cleary J.M., Raghavan S., Wu Q., Li Y.Y., Spurr L.F., Gupta H.V., Rubinson D.A., Fetter I.J., Hornick J.L., Nowak J.A., Siravegna G., Goyal L., Shi L., Brais L.K., Loftus M., Shinagare A.B., Abrams T.A., Clancy T.E., Wang J., Patel A.K., Brichory F., Vaslin Chessex A., Sullivan R.J., Keller R.B., Denning S., Hill E.R., Shapiro G.I., Pokorska-BocciA., Zanna C., Ng K., Schrag D., Jänne P.A., Hahn W.C., Cherniack A.D., Corcoran R.B., Meyerson M., Daina A., Zoete V., Bardeesy N., Wolpin B.M. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021; 11(10): 2488-505. https://doi.org/10.1158/2159-8290.CD-20-1669.
  • Mityushkina N.V., Imyanitov E.N. Molekulyarnaya diagnostika narushenii v genakh semeistva FGFR. Voprosy onkologii. 2023; 69(3): 364-72. https://doi.org/10.37469/0507-3758-2023-69-3-364-372.
  • Boscoe A.N., Rolland C., Kelley R.K. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019; 10(4): 751-65. https://doi.org/10.21037/jgo.2019.03.10.
  • Abou-Alfa G.K., Macarulla T., Javle M.M., Kelley R.K., Lubner S.J., Adeva J., Cleary J.M., Catenacci D.V., Borad M.J., Bridgewater J., Harris W.P., Murphy A.G., Oh D.Y., Whisenant J., Lowery M.A., Goyal L., Shroff R.T., El-Khoueiry A.B., Fan B., Wu B., Chamberlain C.X., Jiang L., Gliser C., Pandya S.S., Valle J.W., Zhu A.X. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6): 796-807. https://doi.org/10.1016/S1470-2045(20)30157-1. Erratum in: Lancet Oncol. 2020; 21(10). Erratum in: Lancet Oncol. 2024; 25(2).
  • Drilon A., Laetsch T.W., Kummar S., DuBois S.G., Lassen U.N., Demetri G.D., Nathenson M., Doebele R.C., Farago A.F., Pappo A.S., Turpin B., Dowlati A., Brose M.S., Mascarenhas L., Federman N., Berlin J., El-Deiry W.S., Baik C., Deeken J., Boni V., Nagasubramanian R., Taylor M., Rudzinski E.R., Meric-Bernstam F., Sohal D.P.S., Ma P.C., Raez L.E., Hechtman J.F., Benayed R., Ladanyi M., Tuch B.B., Ebata K., Cruickshank S., Ku N.C., Cox M.C., Hawkins D.S., Hong D.S., Hyman D.M. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8): 731-9. https://doi.org/10.1056/NEJMoa1714448.
  • DoebeleR.C.,DrilonA.,Paz-AresL.,SienaS.,ShawA.T.,FaragoA.F., Blakely C.M., Seto T., Cho B.C., Tosi D., Besse B., Chawla S.P., Bazhenova L., Krauss J.C., Chae Y.K., Barve M., Garrido-Laguna I., Liu S.V., Conkling P., John T., Fakih M., Sigal D., Loong H.H., Buchschacher G.L. Jr, Garrido P., Nieva J., Steuer C., Overbeck T.R., Bowles D.W., Fox E., Riehl T., Chow-Maneval E., Simmons B., Cui N., Johnson A., Eng S., Wilson T.R., Demetri G.D.; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020; 21(2): 271-82. https://doi.org/10.1016/S1470-2045(19)30691-6. Erratum in: Lancet Oncol. 2020; 21(2). Erratum in: Lancet Oncol. 2020; 21(7). Erratum in: Lancet Oncol. 2020; 21(8). Erratum in: Lancet Oncol. 2021; 22(10).
  • Solomon J.P., Linkov I., Rosado A., Mullaney K., Rosen E.Y., Frosina D., Jungbluth A.A., Zehir A., Benayed R., Drilon A., Hyman D.M., Ladanyi M., Sireci A.N., Hechtman J.F. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020; 33(1): 38-46. https://doi.org/10.1038/s41379-019-0324-7.
  • Romanko A.A., Mulkidjan R.S., Tiurin V.I., Saitova E.S., Preobrazhenskaya E.V., Krivosheyeva E.A., Mitiushkina N.V., Shestakova A.D., Belogubova E.V., Ivantsov A.O., Iyevleva A.G., Imyanitov E.N. Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples. Int J Mol Sci. 2023; 24(18): 14203. https://doi.org/10.3390/ijms241814203.
  • Subbiah V., Cassier P.A., Siena S., Garralda E., Paz-Ares L., Garrido P., Nadal E., Vuky J., Lopes G., Kalemkerian G.P., Bowles D.W., Seetharam M., Chang J., Zhang H., Green J., Zalutskaya A., Schuler M., Fan Y., Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022; 28(8): 1640-5. https://doi.org/10.1038/s41591-022-01931-y.
  • Subbiah V.,WolfJ.,KondaB.,KangH.,SpiraA.,WeissJ.,TakedaM., Ohe Y., Khan S., Ohashi K., Soldatenkova V., Szymczak S., Sullivan L., Wright J., Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022; 23(10): 1261-73. https://doi.org/10.1016/S1470-2045(22)00541-1.
  • Zhou Y., Lizaso A., Mao X., Yang N., Zhang Y. Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report. Ann Transl Med. 2020; 8(17): 1099. https://doi.org/10.21037/atm-20-1007.
  • Valery M., Facchinetti F., Malka D., Ducreux M., Friboulet L., Hollebecque A. Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. Dig Liver Dis. 2021; 53(12): 1664-5. https://doi.org/10.1016/j.dld.2021.09.001.
  • Jakubowski C.D., Mohan A.A., Kamel I.R., Yarchoan M. Response to Crizotinib in ROS1 Fusion-Positive Intrahepatic Cholangiocarcinoma. JCO Precis Oncol. 2020; 4: 825-8. https://doi.org/10.1200/PO.20.00116.
  • Augustin J., Gabignon C., Scriva A., Menu L., Calmel C., Scatton O., Paye F., Fléjou J.F., Praz F., Cervera P., Wendum D. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. VirchowsArch. 2020; 477(1): 33-45. https://doi.org/10.1007/s00428-020-02822-8.
  • Xia H., Zhang J., Chen T., Wang M., Chen D., Si T., Liu Y. Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study. Cancer Med. 2023; 12(13): 14015-24. https://doi.org/10.1002/cam4.6047.
  • Lefler D.S., Tierno M.B., Bashir B. Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. Cancer Biol Ther. 2022; 23(1): 112-6. https://doi.org/10.1080/15384047.2022.2029128.
  • Turpin A., Descarpentries C., Grégoire V., Farchi O., Cortot A.B., Jamme P. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma. Oncologist. 2023; 28(1): 80-3. https://doi.org/10.1093/oncolo/oyac194.
  • Lo J.H., Agarwal R., Goff L.W., Heumann T.R. Lo J.H., Agarwal R., Goff L.W., Heumann T.R. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies. Cancers (Basel). 2023; 15(13): 3312. https://doi.org/10.3390/cancers15133312.
  • Frega G., Cossio F.P., Banales J.M., Cardinale V., Macias R.I.R., Braconi C., Lamarca A. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. Cells. 2023; 12(16): 2098. https://doi.org/10.3390/cells12162098.
  • Marabelle A., Fakih M., Lopez J., Shah M., Shapira-Frommer R., Nakagawa K., Chung H.C., Kindler H.L., Lopez-Martin J.A., Miller W.H. Jr, Italiano A., Kao S., Piha-Paul S.A., Delord J.P., McWilliams R.R., Fabrizio D.A., Aurora-Garg D., Xu L., Jin F., Norwood K., Bang Y.J. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10): 1353-65. https://doi.org/10.1016/S1470-2045(20)30445-9.
  • McGrail D.J., Pilié P.G., Rashid N.U., Voorwerk L., Slagter M., Kok M., Jonasch E., Khasraw M., Heimberger A.B., Lim B., Ueno N.T., Litton J.K., Ferrarotto R., Chang J.T., Moulder S.L., Lin S.Y. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5): 661-72. https://doi.org/10.1016/j.annonc.2021.02.006.
  • Maio M., Ascierto P.A., Manzyuk L., Motola-Kuba D., Penel N., Cassier P.A., Bariani G.M., De Jesus Acosta A., https://doi.org/T., Longo F., Miller W.H., Oh D.Y., Gottfried M., Xu L., Jin F., Norwood K., Marabelle A. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022; 33(9): 929-38. https://doi.org/10.1016/j.annonc.2022.05.519.
  • Yurgelun M.B., Hampel H. Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. Am Soc Clin Oncol Educ Book. 2018; 38: 101-9. https://doi.org/10.1200/EDBK_208341.
  • He W.Z., Huang Y.H., Hu W.M., Wang F., Xu Y.X., Yi J.H., Xue J., Yang Y.Z., Chao X.Y., Lin H.B., Guo G.F., Yun J.P., Xia L.P. Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. Eur J Cancer. 2023; 194. https://doi.org/10.1016/j.ejca.2023.113337.
  • Yin C., Kulasekaran M., Roy T., Decker B., Alexander S., Margolis M., Jha R.C., Kupfer G.M., He A.R. Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition? Cancers (Basel). 2022; 14(10): 2561. https://doi.org/10.3390/cancers14102561.
  • MaynardH.,StadlerZ.K.,BergerM.F.,SolitD.B.,LyM.,LoweryM.A., Mandelker D., Zhang L., Jordan E., El Dika I., Kemel Y., Ladanyi M., Robson M.E., O’Reilly E.M., Abou-Alfa G.K. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer. 2020; 126(9): 1995-2002. https://doi.org/10.1002/cncr.32740.
  • Wardell C.P., Fujita M., Yamada T., Simbolo M., Fassan M., Karlic R., Polak P., Kim J., Hatanaka Y., Maejima K., Lawlor R.T., Nakanishi Y., Mitsuhashi T., Fujimoto A., Furuta M., Ruzzenente A., Conci S., Oosawa A., Sasaki-Oku A., Nakano K., Tanaka H., Yamamoto Y., Michiaki K., Kawakami Y., Aikata H., Ueno M., Hayami S., Gotoh K., Ariizumi S.I., Yamamoto M., Yamaue H., Chayama K., Miyano S., Getz G., Scarpa A., Hirano S., Nakamura T., Nakagawa H. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018; 68(5): 959-69. https://doi.org/10.1016/j.jhep.2018.01.009.
  • Cheng Y., Zhang J., Qin S.K., Hua H.Q. Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report. Onco Targets Ther. 2018; 11: 5957-62. https://doi.org/10.2147/OTT.S176914.
  • Su Y.L., Ng C.T., Jan Y.H., Hsieh Y.L., Wu C.L., Tan K.T. Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. Onco Targets Ther. 2021; 14: 3895-901. https://doi.org/10.2147/OTT.S317514.
  • Zhou T., Mahn R., Möhring C., Sadeghlar F., Meyer C., Toma M., Kreppel B., Essler M., Glowka T., Matthaei H., Kalff J.C., Strassburg C.P., Gonzalez-Carmona M.A. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol. 2022; 12. https://doi.org/10.3389/fonc.2022.933943.
  • Mitiushkina N.V., Tiurin V.I., Anuskina A.A., Bordovskaya N.A., Shestakova A.D., Martianov A.S., Bubnov M.G., Shishkina A.S., Semina M.V., Romanko A.A., Kuligina E.S., Imyanitov E.N. Molecular Analysis of Biliary Tract Cancers with the Custom 3’ RACE-Based NGS Panel. Diagnostics (Basel). 2023; 13(20): 3168. https://doi.org/10.3390/diagnostics13203168.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp